Insmed Gene Therapy

Insmed is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients with serious and rare diseases. The company's lead product, ARIKAYCE, is the first and only FDA-approved therapy for refractory Mycobacterium avium complex (MAC) lung disease. Insmed has significantly expanded its research capabilities through the establishment of a dedicated gene therapy unit, following the acquisition of assets from AAVGene. This division focuses on leveraging advanced adeno-associated virus (AAV) technology to address rare genetic disorders, including Dravet syndrome and Stargardt disease. With a robust pipeline spanning pulmonary, metabolic, and rare genetic conditions, Insmed combines commercial expertise with cutting-edge platform technologies to transform patient care.